Abdol Homayuni Mohammad Reza, Sadeghi Reza, Poshtdar Sepideh, Ramandi Alireza, Nikfar Reza, Ebrahimiadib Nazanin
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
BMC Ophthalmol. 2025 Jul 1;25(1):373. doi: 10.1186/s12886-025-03971-7.
To evaluate the evidence for tamoxifen induced alterations of retina blood flow in macula region, using Optical Coherence Tomography Angiography (OCTA).
A systematic review of PubMed, Google Scholar, Scopus, Web of Science, Cochrane, and Embase databases, including quality assessment of published studies, investigating the alterations of OCTA parameters in Tamoxifen Associated Retinopathy (TAR) was conducted. The outcomes of interest comprised alternations of Vascular Densities (VD) in Superficial and Deep capillary plexus (SCP and DCP) of fovea and parafovea, Telangiectatic vessels (TL), and the Right-Angled Vessels (RAVs).
From the total of 680 articles obtained from the databases, the pool of papers was narrowed down to studies published until May 2024. Lastly, 5 studies were included. Our analysis demonstrated that 80% (95%CI: 63-97%) and 33% (95%CI: 23-44%) of patients on tamoxifen would manifest TL and RAVs in their OCTA, respectively. Tamoxifen patients had lower DCP-F and SCP-F vessel densities; however, only the drop in DCP-F vessel density was statistically significant (MD: -0.46, CI: -0.90 to - 0.01, p-value: 0.04).
Our results show that OCTA findings such as RAV and TL and vascular density DCP-F have been significantly altered compared to healthy controls. These findings demonstrate how OCTA can provide a non-invasive assessment of tamoxifen effects on the retinal microvasculature, potentially serving as a trustworthy biomarker for more accurate TAR identification and monitoring.
使用光学相干断层扫描血管造影（OCTA）评估他莫昔芬引起黄斑区视网膜血流改变的证据。
对PubMed、谷歌学术、Scopus、科学网、Cochrane和Embase数据库进行系统综述，包括对已发表研究的质量评估，调查他莫昔芬相关性视网膜病变（TAR）中OCTA参数的改变。感兴趣的结果包括中央凹和旁中央凹的浅表和深部毛细血管丛（SCP和DCP）中的血管密度（VD）改变、毛细血管扩张血管（TL）和直角血管（RAV）。
从数据库中获得的680篇文章中，论文库被缩小到截至2024年5月发表的研究。最后，纳入了5项研究。我们的分析表明，服用他莫昔芬的患者中，分别有80%（95%CI：63-97%）和33%（95%CI：23-44%）在OCTA中会出现TL和RAV。服用他莫昔芬的患者DCP-F和SCP-F血管密度较低；然而，只有DCP-F血管密度的下降具有统计学意义（MD：-0.46，CI：-0.90至-0.01，p值：0.04）。
我们的结果表明，与健康对照相比，OCTA的结果如RAV、TL和血管密度DCP-F有显著改变。这些发现表明OCTA如何能够对他莫昔芬对视网膜微血管系统的影响进行非侵入性评估，有可能作为一种可靠的生物标志物，用于更准确地识别和监测TAR。
